The INSULINFARCT trial found a significantly higher rate of hypoglycemia in the intensive insulin therapy (IIT) group—5.7% (<54 mg/dL) and 34.5% (<64 mg/dL)—compared to controls. The gene discussed is INS; the disease is Hypoglycemia.